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Cardiac implantable electronic devices are increasing in prevalence and functionality. Post-implant
follow-up is important for monitoring both device function and patient condition. However, practice is
inconsistent. For example, ICD follow-up schedules vary from 3 months to yearly according to facility and
physician preference and availability of resources. Recommended follow-up schedules impose signiﬁcant
burden. Importantly, no surveillance occurs between follow-up visits. In contrast, implantable devices
with automatic remote monitoring capability provide a means for performing constant surveillance, with
the ability to identify salient problems rapidly. Results from large randomized prospective trials of all
types of CIEDs from different manufacturers, and conducted in different countries, consistently indicate
superior performance to conventional care for achieving the current follow-up goals of patient retention
and early problem discovery, improving patient safety and convenience, yet promoting clinic efﬁciencies.
Thus, automatic remote home monitoring is a transforming technology in the evolution of CIEDs, and is
poised for remarkable gains in disease management.
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The implantation of cardiac electronic devices has increased
exponentially during the last decade in response to widening
indications. Subsequent monitoring is an integral part of both devicet Rhythm Society. Published by Elsand patient care. However, follow-up schedules vary according to
facility, physician preference and available resources [1]. A review
of recent US Medicare beneﬁciaries revealed that almost a quarter
of patients were not seen in the year after implant [2]. This
represents a quality of care deﬁcit. To address this, professional
organizations have advocated institution of regular periodic
assessment for patients receiving CIEDs [3]. However, frequent
in-ofﬁce evaluation generates a large service commitment and
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and rate of problem detection have remain unappraised until
recently. This is added to when the volume of unscheduled
encounters periodically increases, for example, when a device
reaches elective replacement indicator (ERI) status or in response
to product advisories or recalls. Symptomatic events (e.g., shock
therapy) prompt additional encounters, including unscheduled
ofﬁce/emergency room (ER) visits or even hospitalization. A major
limitation of this conventional follow-up method, which is based
on patient presentation, is that no monitoring takes place between
hospital visits, i.e., the majority of the time. This will miss
important events especially if asymptomatic, e.g. regarding system
integrity or onset of arrhythmias (e.g. atrial ﬁbrillation (AF)). Their
early detection is critical to patient safety.2. Remote follow-up and remote monitoring
Remote monitoring may be the optimal mechanism for perform-
ing intensive device and patient surveillance, for managing increasing. 1. This 62-year-old woman had a pacemaker implanted previously post-AV nodal ablat
s. In February she had episodes of presyncope. This was due to nonsustained VT noted
low-up transmission in March, following which she was admitted immediately. Her potas
nitoring (e.g. HM or Merlin as in Fig. 2) would have initiated an alert notiﬁcation at timvolume of data, and relieving the burden of routine follow-up
performed by device clinics. In this regard, different functions are
identiﬁed. Remote follow-up involves scheduled automatic device
interrogation, which replaces in-ofﬁce visits aimed at assessing
device function (e.g. battery status, thresholds etc.) The interrogations
can be performed automatically in patients implanted with modern
wireless devices, and manually using wanded home transmitters if
the implanted device is not enabled with wireless technology.
Remote monitoring involves automatic unscheduled transmission of
alert events (e.g. atrial ﬁbrillation, abnormal lead impedance etc.) This
is only possible in some modern wireless devices. Patient initiated
interrogations are non-scheduled follow-ups initiated manually by
the patient as a result of a real or perceived clinical event.3. Remote technologies
The platforms available for remote monitoring of ICDs differ.
Wand-based (“inductive”) systems require patient-driven down-
loads relayed via telephone connections to tracking facilities [4,5].ion for permanent AF. She had had a diarhoeal illness for 3 months with weight
in device diagnostics, but only revealed when she scheduled wanded remote
sium on admission was 2.7 mM. In contrast, a pacemaker with automatic remote
e of occurrence permitting earlier intervention.
N. Varma / Journal of Arrhythmia 29 (2013) 144–152146These are becoming obsolete. This is because they demand
coordination with a device clinic on a calendar-based schedule,
are cumbersome to use, challenge compliance and increase service
burden without offering gain [6,7]. Important diagnostic data may
be overwritten since device diagnostics have ﬁnite memory. Thus,
when used to follow-up a pacemaker population, clinically action-
able events took several months to be discovered, and only 66% of
data were transmitted [8]. These systems remain vulnerable to
late detection of asymptomatic events, or of simply ones that the
patient does not report but are potentially life-threatening (Fig. 1).
In contrast, automatic (wireless or landline) transmission
mechanisms are fully independent of patient and physicianFig. 2. Home monitoring technology-transmission steps. A very-low-power radiofreque
stored data daily to a mobile tranceiver (typically placed bedside at night). The data are
summaries availableonline via secure Internet access. Thus, the patient is monitored d
battery status, lead impedance, and sensing function. Processing is fully automatic, bypas
data may be transmitted immediately and ﬂagged for attention on the HMWeb page. Au
transmission of intracardiac electrograms (IEGM-online snapshots) similar to those avail
for early detection and enables prompt clinical intervention, if necessary. Daily transmi
Source: compiled with permission from [50].
Fig. 3. TRUST study. Top left: study design—remote monitoring vs. conventional care; top
bottom right: early detection of silent problems.
Compiled with permission from Ref. [11].interaction (Fig. 2). (This makes them particularly suitable for
children [9] and the elderly). Data may be reviewed securely via
the Internet. This system was pioneered by Home Monitorings
(HM) (Biotronik, Berlin, Germany) with excellent reliability and
early notiﬁcation ability [10]. 90% Of transmitted data were received
within 5 min with greater than 99% data ﬁdelity. ICD generators
were shown to self-declare problems promptly irrespective of
interrogation schedules or associated symptoms [11,12]. System
operation is not energy costly [13]. This technology has the ability to
maintain surveillance and rapidly bring to attention signiﬁcant data,
enabling clinically appropriate intervention. These potentials have
been tested prospectively in recent trials.ncy transmitter circuitry integrated within the pulse generator wirelessly transmits
relayed via landline or wirelessly to a service center which generates customized
aily, and trend analysis information is compiled from typical follow-up data: e.g.,
sing potential delays (and errors) associated with manual processing. Critical event
tomatic alerts occur for silent but potentially dangerous events. These alerts include
able during ofﬁce-based device interrogations. This technology provides the ability
ssion load had no effect on battery longevity in the TRUST trial [13].
right: effect on clinic volumes per year; bottom left: early detection of arrhythmias;
N. Varma / Journal of Arrhythmia 29 (2013) 144–152 1474. Clinical trials
The ﬁrst large remote monitoring trial was TRUST [11,14]. This
randomized almost 1500 patients to remote management with
HM or conventional face-to-face evaluations (Fig. 3, top left). HM
promoted greater adherence to long-term follow-up without
compromizing safety (this safety endpoint was endorsed in the
ECOST trial during longer follow-up [15]). When inclusive of all
patient encounters, (i.e. scheduled and unscheduled), health care
utilization was reduced by 50% (Fig. 3, top right). The second
important result of TRUST was demonstration of early detection
ability of clinical events during continuous remote monitoring.
Despite extension of intervals between face-to-face encounters to
yearly, event onset to physician evaluation of combined ﬁrst AF,
VT and VF events in HM was 1 day, dramatically less than in
conventional care (41 month) with frequent face to face encoun-
ters (Fig. 3, bottom left). Importantly, early detection was main-
tained for silent problems (Fig. 3, bottom right). (This ability was
inconceivable even a few years previously with wanded remote
systems when detection at 5.7 months was considered “early” [8]).
Similar beneﬁts were seen in pacemaker recipients in the COMPAS
trial [16]. Interestingly, the results suggested that remote monitor-
ing could have an impact to decrease atrial arrhythmia and stroke
related hospitalizations. The HomeGuide Registry conﬁrmed
that the high quality of remotely acquired data since the majority
(480%) of clinically meaningful events were remotely detected
(sensitivity 84%; positive predictive value 97%) [17].
The CONNECT trial followed up to TRUST with a similar study
design but with a different wireless remote technology (Medtronic
CareLink Network) in a separate ICD population [18]. The results
conﬁrmed that remote interrogation effectively substituted for in-
ofﬁce visits and provided early detection capability. However,
safety was not assessed. Furthermore, the susceptibility of this
technology platform to transmission failure and the negative
effects of multiple transmission attempts on battery longevity
are signiﬁcant drawbacks [19]. When alert transmissions for some
conditions were successful, manual reset was required to reacti-
vate this notiﬁcation ability, i.e. the ability for further notiﬁcation
in the interim was lost until an otherwise unnecessary in-person
encounter could be arranged. This design, depending on patient
interaction and single transmissions vulnerable to failure, limits its
role as an early-warning mechanism.5. The follow-up clinic
These trial results have signiﬁcant implications for clinic efﬁ-
ciencies. The safe and effective replacement of the bulk of “routine”
in-clinic evaluations demonstrated in TRUST (Fig. 3) has a huge
implication for resource utilization. Although demanding adjust-
ment to different workﬂow patterns (and mindsets), especially for
alert notiﬁcations, this is more than balanced by the great reduction
of routine non-actionable in-person evaluations. This was amply
demonstrated by Ricci et al. using HM [17,20]. Prior to implementa-
tion of this innovative technology, all involved personnel, including
patients, were primed to process and expectations. The results were
astonishing: the median committed monthly manpower was
55.5 min health personnel per 100 patients with a range of CIEDs.
This was based on a cooperative interaction between a reference
nurse and a responsible physician with an agreed list of respective
tasks and responsibilities. Although demanding extra resources,
nurse-based remote patient management improves follow-up qual-
ity, generates manpower efﬁciencies and directs only problematic
remote assessments (which occur infrequently) to physicians other-
wise released to their other assignments.The HomeGuide results highlighted the key role of a trained
dedicated allied professional, especially important for maintaining
early reaction ability. However, resources to operate such a virtual
clinic may not be universally available. Other options, to be fully
developed, include industry-supported units (e.g. in Asia-Paciﬁc
[21]) or third party service providers directing information from all
proprietary technologies to a single readily accessible (Web-based)
platform. Patient engagement is important to successful remote
management and acceptance and satisfaction of HM has been high
[22]. Communication, initially education regarding its function
to enhance overall clinical management (and not an emergency
system), should be continued since heart disease is a dynamic
condition and needs (medications, programming, in-person eva-
luations) change with time. This is obviously essential when
retrieved data drive treatment e.g. physician-directed patient
self-management based on direct hemodynamic measurements
[23]. It is important to note that HM does not supplant the ﬁrst
post-implant in-person evaluation [3] important for assessment of
wound healing, determination of chronic thresholds and setting
of ﬁnal pacing parameters. Problems such as lead perforations
or failures requiring revision and symptomatic reactions to
implantation (e.g. pacemaker syndrome, diaphragmatic pacing
and pocket infection) cluster in this early post-implant. They occur
more frequently with dual-chamber or resynchronization units
[24–26].6. Device management
Remote monitoring with capability for same day discovery of
problems (even when asymptomatic), when appropriate technol-
ogy and clinic infrastructure are in place [27], may profoundly affect
patient management. The most obvious application of remote
monitoring is for detection of system dysfunction [12,28]. Although
safety concerns underpinned original post-implant follow-up sche-
dules e.g. for assessing pacing thresholds, integrity of components
and charging capacitors, these issues now belong to a different era.
Current generation devices require no such maintenance, have
extreme reliability, and perform an array of autoregulatory func-
tions. Nevertheless, early detection of system perturbations, espe-
cially for components subject to advisories, remains an imperative.
This underlies the original announcements from professional
societies for “device manufacturers use wireless and remote mon-
itoring technologies to identify device malfunctions in a timely
manner and to increase the accuracy of detecting and reporting
device malfunctions”, carrying the expectation of early detection
and correction of device malfunction [29,30].
TRUST conﬁrmed that conventional monitoring methods
underreport device related problems (Fig. 4) [12]. Automatic
remote monitoring, in contrast, enhanced the discovery of system
problems (even when asymptomatic) and enabled prompt clinical
decisions regarding conservative versus surgical management.
Most ICD system malfunctions could be identiﬁed within 24 h
of occurrence even though performance problems were often
asymptomatic [27]. [In contrast, these would remain quiescent
with conventional follow-up or even wanded remote systems
(Fig. 1)]. Reprogramming changes accounted for the majority of
“actionable” interrogations in the TRUST trial [11]. This is impor-
tant since programming may directly affects mortality [31]. Results
of ECOST secondary analyses have high clinical value [15]. Clinical
reactions enabled by early detection resulted in a large reduction
in the number of actually delivered shocks (−72%), the number of
charged shocks (−76%), the rate of inappropriate shocks (−52%)
and at the same time exerting a favorable impact on battery
longevity. Reduced generator replacements, aside from cost issues,
avoid the considerable morbidity associated with this surgery.
Fig. 4. Left: event-free survival rates in home monitoring (HM) patients compared with conventional care group. The observed time to the ﬁrst event was shorter in HM.
Although the incidence of patients developing system problems was similar in both groups, these incidents were considerably underreported with conventional care. Right:
an example of an asymptomatic event. Nonphysiological signals: electromagnetic interference (EMI). Event notiﬁcation received for an aborted shock detected at 7:16 pm
The accompanying automatic, wirelessly transmitted electrogram shows gross artifact on both atrial and ventricular leads. The subject was asymptomatic but, in response to
the notiﬁcation, was seen in-ofﬁce within 24 h. (Asymptomatic detections meeting ventricular ﬁbrillation [VF] detection criteria resulted in immediate event notiﬁcations
with accompanying wireless electrogram transmission, even if shock therapy was aborted.)
Source: compiled with permission from [12].
Fig. 5. Home Monitorings (Biotronik) generator coupled to a Sprint Fideliss (MDT 6949) (Medtronic) lead. Two event notiﬁcations that were transmitted immediately on
occurrence of lead fracture, occurring silently during sleep at 4:43 am, 6 weeks after last clinic follow-up on November 14. Left Ppanel: lead impedance alert. Lead impedance
trend had been stable below 600 Ω in prior weeks but then suddenly increased 4500 Ω, triggering an event notiﬁcation (red) (although this absolute value was still within
speciﬁcations). Right panel: the second event report is a separate notiﬁcation responding to the same event, indicating two occurrences of detection in VF zone (top) and
ﬂagged (red exclamation mark on yellow background). The accompanying wirelessly transmitted electrogram demonstrated irregular sensed events (markers indicate
coupling intervals as short as 78 ms) with VF detection (marked). No therapy was delivered, indicating spontaneous event termination. [Electrogram deﬁnition is modest in
ﬁrst-generation device with wireless intracardiac electrogram transmission (Lumos). Current devices transmit electrograms with improved resolution (1/128 s) and longer
duration, including postdetection sequences (see, e.g., Fig. 4)]. The clinic received these notices and informed the patient, whose case was then reviewed urgently within 24 h
and treated with lead extraction and replacement. This case demonstrates the value of remote monitoring with daily automatic surveillance and rapid, automatic (without
patient participation) event notiﬁcation to the clinic when a fault is detected, enabling prompt intervention. The addition of nonsustained VT events to the impedance
deviation improved the speciﬁcity of detection of lead failure. Without HM, the patient may have presented later with inappropriate shocks or, more catastrophically, with
failure of pacing or VF sensing.
Source: compiled with permission from [32].
N. Varma / Journal of Arrhythmia 29 (2013) 144–152148Avoiding inappropriate shocks is one of the most challenging
aspects of ICD management. Although the merits of correct
programming of ICD detection parameters are crucial to the
occurrence of inappropriate therapies, the ECOST study brought
the novel observation that automatic remote home monitoring is
also an instrument to decrease the incidence of inappropriate
therapy.7. Recalls and advisories
Managing components under advisory notices poses several
daunting challenges. Fig. 5 illustrates the beneﬁt of HM for the
management of recalled components [29,32]. Advisories encom-
pass disintegration of high-voltage circuitry, battery depletion,
and lead failure—almost all of which are captured by currently
Fig. 6. Alert notiﬁcation received on Merlin.net for ST-segment shift in a 57-year-old man with a prophylactic ICD implanted for ischemic cardiomyopathy.
Courtesy of Gary Cranke BS, St Jude Medical.
Fig. 7. Interrogation of a conventional CRT-D device in the clinic following patient presentation with acute decompensated heart failure. (Compiled with permission from
Ref. [51]). If coupled to remote monitoring, advent of AF and loss of CRT pacing (insets) would have been event-notiﬁed (red dots) several weeks prior to symptomatic
deterioration, possibly enabling early pre-emptive therapy.
N. Varma / Journal of Arrhythmia 29 (2013) 144–152 149evaluated event triggers [33,34]. In comparison, conventional
detection methods, such as increasing the frequency of ofﬁce
visits [35] are impractical, burdensome, and likely to missdangerous interim problems. Patient alert mechanisms, such as
beeps, are insensitive and prone to false-positive evaluations [36].
In contrast, HM generators trigger immediate alerts when data
N. Varma / Journal of Arrhythmia 29 (2013) 144–152150deviate from established trends. This reduces the burden both for
patients who frequently monitoring their own devices and for
clinics who are responsible for large cardiac patient populations
that have a low incidence of typically silent problems. The ability
to collect detailed, device-speciﬁc data, and to assess component
function daily and automatically archive the information, sets a
precedent for the long-term evaluation of lead and generator
performance. Technology differences may affect early detection
capability. Early discovery can be improved with repeated messa-
ging in the instance that the initial clinic notiﬁcation was missed
[27].
Remote monitoring for device function has great beneﬁt
for patients. It may facilitate management of unscheduled encoun-
ters provoked by device related symptoms. For example, an
appropriate or phantom ICD shock could be managed simply with
a reassuring telephone conversation. However, in-person evalua-
tion may be recommended if physician and/or patient expressed
any reservation regarding reconciliation of stated symptoms
with remotely acquired data. There is increasing patient concern
regarding function of their implanted devices, despite the great
overall reliability of implantable technology in general. Patients
who have received inappropriate shocks or informed of recalled
components may be particularly apprehensive. In this regard,
remote monitoring (rather than remote follow-up at pre-set
intervals) is especially assuring.8. Disease management
Recipients of ICDs and CRTs commonly have other comorbid-
ities, e.g. coronary artery disease, which may be tracked.
ST-segment shifts may be recorded from unipolar electrograms
derived from right ventricular lead tip to can. When linked to
automatic remote monitoring, this feature may permit early
diagnosis of myocardial ischemia and treatment or prevent unne-
cessary hospital presentation for non-cardiac chest pains (Fig. 6).
The predictive value of this remote alert to enable clinical
decisions is currently being evaluated in trials. Continuous mon-
itoring may also aid management of the current epidemics of HF
and AF [37].9. Heart failure
In CHF, non-implantable technologies, depending on patient
compliance and following non-speciﬁc parameters, have been
unhelpful [38]. Preliminary signals indicate beneﬁt from remote
monitoring e.g. the signiﬁcant shortening of hospital length of stay
and reduced overall hospital costs [18]. Device-based physiologic
information and diagnostics indicate that several interdependent
cardiovascular factors (arrhythmias and paced burden shifts,
intrathoracic impedance, vagal withdrawal, intracardiac hemody-
namics) may change several days to weeks before ultimate
hospitalization [39] (Fig. 7). A combined risk score incorporating
all of these individual factors may improve their predictive value
[40], creating an opportunity for early pre-emptive intervention.
Success will depend on accurate longitudinal parameter trends
(preferably updated daily) and early notiﬁcation for out-of-bounds
parameter groups. These can be delivered by remote monitoring.
Although results with thoracic impedance have been inconsistent
[41], other sensors appear more positive [23] and provide notiﬁcation
of conditions that lead to decompensation and prompt rapid pre-
emptive therapy for them. In this regard, CHAMPION trial results are
sentinel, illustrating that action taken on remotely acquired data
(from a CIED with no inherent therapeutic ability) reduced patientmorbidity and averted hospitalization. This changes the paradigm of
CIED function.10. Atrial ﬁbrillation
AF event notiﬁcations are commonly received during automatic
remote surveillance. These data may inﬂuence important clinical
decisions to treat or prevent stroke, ventricular arrhythmias,
and heart failure. However, diagnosing AF events is challenging.
The ability to detect this evanescent and largely asymptomatic
arrhythmia early, by automatic remote monitoring, may permit
early treatment [10]. For example, starting anticoagulants, con-
trolling heart rate for rapid ventricular rates that may elicit
inappropriate shock therapy or lead to heart failure, or reversion
to normal sinus rhythm. The potential beneﬁt for stroke risk
reduction by remote monitoring was modeled on a real population
of 166 patients. The results suggested that daily monitoring may
reduce the 2-year stroke risk by 9%–18% with an absolute reduc-
tion of 0.2% –0.6%9, compared to conventional inter-visit intervals
of 6–12 months [42]. The COMPAS trial randomized 538 pace-
maker patients and noted that the incidence of hospitalizations for
atrial arrhythmias and related stroke was 0.073 in the control
group and 0.024 in the remote monitoring group (p¼0.02), with a
stroke rate of 0.033 and 0.008 respectively [16]. However, COMPAS
was not powered to test this hypothesis. The interaction of AF and
HF is particularly deleterious. One large multicenter study (1193
CRT-D patients from 44 Italian centers) reported signiﬁcantly
higher freedom from the composite endpoint of death or heart
transplantation or heart failure hospitalization in patients in sinus
rhythm than in those with AF [43]. AF associated with periods of
rapid ventricular conduction reduces beneﬁts of CRT [44]. With-
drawal of ventricular pacing in CRT-D is immediately notiﬁed
during remote monitoring (Fig. 7).11. Mega-cohort studies
Remote monitoring collects a wealth of data from large
numbers of patients which are not subject to saturation or over-
written memory counters within any implantable device. These
databases provide an opportunity to better understand system
function, patient condition, and disease progression in “real-world”
subjects, as opposed to more narrowly deﬁned enrollees in
relatively short term trials. Long-term parameter trends derived
from these databases will provide important measures of system
performance, e.g., generator and lead survival. Automatically
archived data will also permit accurate follow-up of patient
morbidities. For example, AF is difﬁcult to characterize in practice,
but remote monitoring permits clinicians to interpret arrhythmia
patterns, absolute AF burden, degree of temporal dispersion, and
progression to persistent arrhythmia. These factors may help
clinicians to understand the risks this condition poses and to
optimize its management. These questions are being addressed, in
particular by the ALTITUDE committee [45].12. Persistent challenges
Challenges exist e.g. for data management. Although remote
monitoring results in lesser in-person evaluations, receiving facil-
ities have to handle a signiﬁcant volume of remotely acquired
data. However, appropriate programming and a degree of inbuilt
processing resulted in a low event notiﬁcation rate with Home
Monitoring, and when sent, alerts carried high predictive value for
actionability [22,46,47]. The ability to process several parameters
and notify deviation in a pre-speciﬁed combination improves the
N. Varma / Journal of Arrhythmia 29 (2013) 144–152 151speciﬁcity of alerts e.g. for lead fracture or heart failure detection
[40,48]. Transferring this computing responsibility from implanted
unit (necessarily limited) to an external service center is an
important advantage of wirelessly transmitted data with high
frequency and may enable some detection algorithms [49]. Con-
cerns exist about liability posed and data overload, and above all
cost. Liability concerns center around alerts received but not acted
on, although remote monitoring is not an emergency system.
However, the author is unaware of any legal challenges occurring
in over a decade of use of automatic remote monitoring. The
counterargument is that, since remote monitoring outperforms
traditional methods, future questions may be directed to why the
security of comprehensive coverage was not chosen. The cost of
the implantable technology cannot be ignored. Costs to manufac-
turer result from embedded transmission system, the transceiver,
warranties and running costs of cellular transmissions. Enabled
devices command premium rates, beyond already formidable
levels, for self paying patients.13. Summary
Results from large randomized prospective trials of all types of
CIEDs from different manufacturers, and conducted in different
countries, consistently indicate superior performance to conven-
tional care for achieving the current follow-up goals of patient
retention and early problem discovery, improving patient safety
and convenience, yet promoting clinic efﬁciencies. The call from
professional organizations for development of intensive and com-
prehensive monitoring of implantable devices, to better manage
CIEDS, has been well met by modern remote monitoring technol-
ogies [29,30]. However, their capabilities extend beyond this and
may enable clinical interventional strategies aiming to inﬂuence
disease progression (e.g. heart failure) which demand frequent
data collection with early notiﬁcation of parameter deviations
[40]. This intent has been thwarted previously when using systems
relying on patient participation, which wanes rapidly over pro-
longed time periods [38], but this problem is avoided by automatic
remote monitoring. Thus, a retrospective analysis of almost 70,000
subjects from the ALTITUDE Safety Study database suggested that
patients assigned to remote management had improved survival
[45] i.e. use of this technology has a direct and positive effect on
patient outcomes.
In conclusion automatic remote home monitoring is a trans-
forming technology in the evolution of CIEDs, enabling rigorous
CIED surveillance, and is poised for remarkable gains in disease
management.Conﬂict of interest
NV receives research grants, fellowship support and/or speaker
honoraria from Biotronik, Boston Scientiﬁc, Medtronic, and St-Jude
Medical.
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